Chapter 411: Men’s Health¶
Chapter 411 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Men’s health is a distinct discipline due to sex-specific differences in disease susceptibility, clinical manifestations, and treatment responses.
- Testosterone deficiency in older men is associated with reduced muscle mass, bone density, sexual dysfunction, and increased cardiovascular risk.
- Anabolic-androgenic steroid (AAS) abuse is linked to severe cardiovascular, endocrine, and musculoskeletal complications, including liver damage and psychiatric disorders.
- Lower urinary tract symptoms (LUTS) are common in older men and often associated with benign prostatic hyperplasia, but may have multifactorial etiologies.
- Androgen deprivation therapy (ADT) for prostate cancer increases cardiometabolic risks, requiring careful monitoring and lifestyle interventions.
1. DEFINITION & OVERVIEW¶
Men’s health as a discipline addresses sex-specific differences in disease biology, clinical outcomes, and healthcare access. Key areas include testosterone physiology, sexual dysfunction, substance abuse, and prostate health. The chapter emphasizes the importance of individualized care for conditions like hypogonadism, muscle dysmorphia, and LUTS.
Table 411-1: Association of Testosterone Levels with Outcomes in Older Men¶
| Positive Associations | Negative Associations | Not Associated |
|---|---|---|
| Muscle mass, physical function, sexual desire, bone density | Coronary artery disease, type 2 diabetes, metabolic syndrome, mortality, falls, dementia | Lower urinary tract symptoms, erectile dysfunction, major depression |
1.1 Sex Differences in Disease Susceptibility¶
Men and women differ in disease prevalence, clinical manifestations, and treatment responses. For example, men have higher rates of neurodegenerative disorders, substance use disorders, and certain cancers (e.g., prostate, pancreatic), while women have higher autoimmune and osteoporosis risks. These differences are influenced by hormonal, genetic, and socioeconomic factors.
1.2 Substance Abuse and Violence¶
Men have higher rates of alcohol and tobacco use, contributing to increased mortality from accidents, suicides, and homicides. Intimate partner violence (IPV) is a leading cause of death in young women, with significant mental health and social consequences.
2. EPIDEMIOLOGY¶
Testosterone levels decline with age, affecting 2.1% of men aged 40–70 years with total testosterone <317 ng/dL and free testosterone <64 pg/mL. Hypogonadism is linked to increased mortality in middle-aged men, particularly in regions like Appalachia and New England. AAS abuse is more prevalent among recreational weightlifters and bodybuilders.
Table 411-2: Potential Benefits of Testosterone Replacement Therapy¶
| Strong Evidence of Efficacy | Suggestive Evidence | Evidence of Lack of Efficacy |
|---|---|---|
| Sexual function, depressive symptoms, bone density, anemia correction | Mobility improvement | Cognitive function, erectile dysfunction |
2.1 Risk Factors¶
Advanced paternal age, obesity, comorbid conditions (e.g., diabetes, cardiovascular disease), and socioeconomic factors contribute to male-specific health risks. AAS use is associated with higher rates of cardiovascular events, liver damage, and psychiatric disorders.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Testosterone decline with aging involves defects in the hypothalamic-pituitary-testicular (HPT) axis, reduced Leydig cell function, and altered SHBG levels. AAS abuse disrupts endocrine function, suppresses gonadotropin secretion, and induces hepatic toxicity. Sex differences in immune responses and hormonal regulation contribute to disease susceptibility.
Table 411-3: Adverse Events of Testosterone Replacement Therapy¶
| Strong Evidence | No Evidence | Weak Evidence |
|---|---|---|
| Erythrocytosis, venous thromboembolism, prostate cancer | Major cardiovascular events | Atrial fibrillation, bone fractures |
3.1 Hormonal Mechanisms¶
Testosterone deficiency leads to reduced muscle mass, bone density, and sexual function. AAS use causes suppression of endogenous testosterone production, hepatic damage, and cardiovascular risk due to dyslipidemia and thrombosis.
4. CLINICAL FEATURES¶
Symptoms of hypogonadism include reduced libido, fatigue, erectile dysfunction, and osteoporosis. AAS abuse is associated with acne, gynecomastia, and cardiovascular complications. LUTS manifest as storage, voiding, or postmicturition symptoms, often linked to benign prostatic hyperplasia or neurogenic bladder dysfunction.
Table 411-4: Adverse Effects of Anabolic-Androgenic Steroids¶
| Cardiovascular | Endocrine | Neuropsychiatric | Musculoskeletal |
|---|---|---|---|
| Hypertension, sudden death, cardiomyopathy | HPT suppression, gynecomastia | Mood disorders, aggression, dependence | Tendon injuries, musculoskeletal pain |
4.1 Sexual Dysfunction¶
Erectile dysfunction and decreased libido are common in older men. AAS withdrawal can exacerbate these symptoms, while testosterone replacement may improve sexual function in hypogonadal men.
5. DIFFERENTIAL DIAGNOSIS¶
For hypogonadism, differentiate between primary (testicular failure) and secondary (HPT axis dysfunction). For LUTS, consider benign prostatic hyperplasia, neurogenic bladder, or bladder neck obstruction. AAS abuse must be distinguished from endogenous testosterone deficiency or other endocrine disorders.
5.1 Hypogonadism¶
Primary hypogonadism (testicular failure) vs. secondary (pituitary or hypothalamic dysfunction). Klinefelter syndrome and testicular cancer are differential diagnoses for male infertility.
6. INVESTIGATIONS & DIAGNOSIS¶
Measure total and free testosterone, SHBG, LH, and FSH. Use urinary testosterone-to-epitestosterone ratio and isotope ratio mass spectrometry for AAS detection. Imaging (e.g., MRI) and urodynamic studies aid in diagnosing LUTS. Prostate-specific antigen (PSA) and bone density scans are critical for prostate cancer and osteoporosis evaluation.
Table 411-5: Detection of Anabolic-Androgenic Steroid Use¶
| Clinical Indicators | Laboratory Indicators | Detection Methods |
|---|---|---|
| Muscular phenotype, reduced testicular volume | Suppressed LH/FSH, increased hematocrit | LC-MS/MS, isotope ratio analysis |
6.1 Diagnostic Criteria¶
Hypogonadism is diagnosed with total testosterone <317 ng/dL and free testosterone <64 pg/mL in men aged 40–70 years. AAS use is confirmed by urinary testosterone-to-epitestosterone ratio >4 or isotope analysis.
7. MANAGEMENT & TREATMENT¶
Testosterone replacement therapy (TRT) is indicated for hypogonadism with symptoms, but requires monitoring for cardiovascular and thromboembolic risks. AAS dependence is managed with cognitive-behavioral therapy, pharmacologic agents (e.g., clomiphene, hCG), and lifestyle interventions. LUTS are treated with α -adrenergic antagonists, 5 α -reductase inhibitors, or PDE5 inhibitors.
Table 411-6: Checklist for Men Undergoing ADT¶
| Key Actions | Monitoring Parameters |
|---|---|
| Baseline assessment, calcium/vitamin D optimization | Bone density, lipid profile, glucose, FRAX score |
7.1 Testosterone Replacement¶
TRT improves sexual function, bone density, and muscle mass but carries risks of erythrocytosis and cardiovascular events. It is contraindicated in men with prostate cancer or a history of thromboembolism.
8. PROGNOSIS & COMPLICATIONS¶
Hypogonadism is associated with increased mortality, frailty, and cardiovascular risk. AAS abuse leads to severe complications, including liver failure, cardiovascular events, and psychiatric disorders. ADT for prostate cancer increases fracture risk, diabetes, and metabolic syndrome.
9. SPECIAL CONSIDERATIONS¶
Testosterone therapy in men with a history of prostate cancer requires close monitoring of PSA levels. AAS use in adolescents and young men is linked to long-term cardiovascular and psychiatric risks. Men with diabetes or cardiovascular disease require careful management of TRT and ADT.
10. KEY POINTS & CLINICAL PEARLS¶
- Testosterone deficiency in older men is linked to reduced quality of life and increased mortality.
- AAS abuse is a growing public health concern with severe cardiovascular and metabolic consequences.
- LUTS are multifactorial and require individualized management.
- ADT for prostate cancer requires careful monitoring for cardiometabolic complications.
- Men’s health care must address sex-specific biological and social determinants of disease.